COGR Submits Letter to DEA Regarding Production Quotas for Schedule I & II Controlled Substances

COGR submitted formal comments to the U.S. Drug Enforcement Administration (DEA) regarding the proposed 2019 aggregate production quotas for Schedule I and II controlled substances, with particular attention to marijuana and its derivatives. COGR expressly supports the proposed increase in production quotas for marijuana and tetrahydrocannabinols, seeing this as a constructive move to advance scientific research. The organization emphasizes the importance of timely action by the DEA on pending applications from entities seeking to manufacture marijuana for research purposes, highlighting that both increased quotas and additional approved manufacturers would enhance universities’ ability to conduct critical research. COGR argues that such measures would not only contribute to a deeper understanding of marijuana’s therapeutic potential but also facilitate studies on related subjects, including drug interactions and public health risks, in the context of expanded state-level legalization for medical and recreational use. The Council further underscores the broader implications for public health and public policy and encourages ongoing collaboration between federal and state agencies to maximize research benefits. The letter closes with an offer for continued dialogue, providing contact information for further engagement.